A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST)

被引：0
|
作者：
Moulder, S. [1 ]
Adrada, B. [1 ]
Lim, B. [1 ]
Ueno, N. [1 ]
Candelaria, R. [1 ]
Rauch, G. [1 ]
Litton, J. [1 ]
Thompson, A. [2 ]
Huo, L. [1 ]
Hess, K. [1 ]
机构：
[1] Univ TX MD Anderson Canc Ctr, Houston, TX USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
BREAST | 2019年 / 44卷
关键词：
D O I：
10.1016/S0960-9776(19)30349-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P248
引用
收藏
页码：S101 / S102
页数：2
相关论文
共 50 条
  • [41] Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.
    Von Minckwitz, Gunter
    Hahnen, Eric
    Fasching, Peter A.
    Hauke, Jan
    Schneeweiss, Andreas
    Salat, Christoph
    Rezai, Mandi
    Blohmer, Jens U.
    Zahm, Dirk Michael
    Jackisch, Christian
    Gerber, Bernd
    Klare, Peter
    Kummel, Sherko
    Eidtmann, Holger
    Paepke, Stefan
    Nekljudova, Valentina
    Le Loibl, Sibyl
    Untch, Michael
    Schmutzler, Rita K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
    Guo, Xuhui
    Zhang, Jiao
    Gong, Xilong
    Wang, Jia
    Dai, Hao
    Jiao, Dechuang
    Ling, Rui
    Zhao, Yi
    Yang, Hongjian
    Liu, Yunjiang
    Liu, Ke
    Zhang, Jianguo
    Mao, Dahua
    He, Jianjun
    Yu, Zhigang
    Liu, Yinhua
    Fu, Peifen
    Wang, Jiandong
    Jiang, Hongchuan
    Zhao, Zuowei
    Tian, Xingsong
    Cao, Zhongwei
    Wu, Kejin
    Song, Ailin
    Jin, Feng
    Fan, Zhimin
    Liu, Zhenzhen
    BREAST, 2024, 73
  • [43] Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
    Sikov, W. M.
    Berry, D. A.
    Perou, C. M.
    Singh, B.
    Cirrincione, C.
    Tolaney, S.
    Kuzma, C. S.
    Pluard, T. J.
    Somlo, G.
    Port, E.
    Golshan, M.
    Bellon, J. R.
    Collyar, D.
    Hahn, O. M.
    Carey, L. A.
    Hudis, C.
    Winer, E. P.
    CANCER RESEARCH, 2013, 73
  • [44] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
    Gianni, Luca
    Huang, Chiun-Sheng
    Egle, Daniel
    Bermejo, Begona
    Zamagni, Claudio
    Thill, Marc
    Anton, Antonio
    Zambelli, Stefania
    Bianchini, Giampaolo
    Russo, Stefania
    Ciruelos, Eva
    Greil, Richrad
    Semiglazov, Vladimir
    Colleoni, Marco
    Kelly, Catherine
    Mariani, Gabriella
    Del Mastro, Lucia
    Maffeis, Ilaria
    Valagussa, Pinuccia
    Viale, Giuseppe
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Multiple- parameter MRI after neoadjuvant systemic therapy combining clinicopathologic features in evaluating axillary pathologic complete response in patients with clinically node- positive breast cancer
    Chen, Minglei
    Xu, Zeyan
    Zhu, Chao
    Liu, Yulin
    Ye, Yunrui
    Liu, Chen
    Liu, Zaiyi
    Liang, Changhong
    Liu, Chunling
    BRITISH JOURNAL OF RADIOLOGY, 2022, 95 (1139):
  • [46] An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
    Chung, Wai-Shan
    Chen, Shin-Cheh
    Ko, Tai-Ming
    Lin, Yung-Chang
    Lin, Sheng-Hsuan
    Lo, Yung-Feng
    Tseng, Shu-Chi
    Yu, Chi-Chang
    CANCERS, 2022, 14 (17)
  • [47] Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumours exhibiting low-overall change in molecular profile after neoadjuvant therapy
    Abuhadra, N.
    Seth, S.
    Moulder, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 84 - +
  • [48] Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc
    Sikov, William M.
    Barry, William T.
    Hoadley, Katherine A.
    Pitcher, Brandelyn N.
    Singh, Baljit
    Tolaney, Sara M.
    Kuzma, Charles S.
    Pluard, Timothy J.
    Somlo, George
    Port, Elisa R.
    Golshan, Mehra
    Berry, Donald A.
    Hahn, Olwen M.
    Carey, Lisa A.
    Perou, Charles M.
    Hudis, Clifford A.
    Winer, Eric P.
    CANCER RESEARCH, 2015, 75
  • [49] Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse
    Groheux, David
    Hindie, Elif
    Giacchetti, Sylvie
    Delord, Marc
    Hamy, Anne-Sophie
    de Roquancourt, Anne
    Vercellino, Laetitia
    Berenger, Nathalie
    Marty, Michel
    Espie, Marc
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (02) : 249 - 254
  • [50] Correlation of quantitative p95HER2 and HER2 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant (NEO) trastuzumab-containing therapy.
    Villasboas, Jose Caetano
    Hurley, Judith
    Weidler, Jodi Marie
    Paquet, Agnes
    Fernandez, Carmen Gomez
    Lavina, Maureen Cioffi
    Sperinde, Jeff
    Chenna, Ahmed
    Haddad, Mojgan
    Lie, Yolanda
    Winslow, John William
    Huang, Weidong
    Petropoulos, Christos J.
    Pegram, Mark D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345